This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) Q1 results benefit from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, segmental growth and raised 2019 EPS outlook benefit AmerisourceBergen's (ABC) Q3 earnings.
Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.
CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.
ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan
by Zacks Equity Research
ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.
IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.
Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.
QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View
by Zacks Equity Research
QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.
The Zacks Analyst Blog Highlights: Alphabet, Intel, PayPal, Starbucks and Stryker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Intel, PayPal, Starbucks and Stryker
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Ecolab (ECL) gains from solid segmental contributions in the second quarter. It retains 2019 EPS view.
Top Research Reports for Alphabet, Intel & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Intel (INTC) and PayPal (PYPL).
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
Stryker (SYK) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 2.59% and 1.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Large Corporates Set to Beat on Earnings in Q2 Today
by Nalak Das
Wall Street's benchmark index, the S&P 500, and tech-laden Nasdaq Composite achieved fresh all-time highs on Jul 24, buoyed by strong earnings results.
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
Why Stryker (SYK) Might Surprise This Earnings Season
by Zacks Equity Research
Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat
by Zacks Equity Research
Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.